Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 338 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Comparative Effectiveness Study Clear all

Conditions: Health Services Accessibility, Rural Health, Medically Underserved Area, Preventive Health Services, Patient Participation, Health Behavior, Aging, Cardiovascular Diseases, Metabolic Syndrome, Cognitive Dysfunction, Frailty, Activities of Daily Living, Health Related Quality of Life, Health Equity, Telemedicine
Interventions: AI-Assisted Screening Interpretation (AI Reads), Human-Only Screening Interpretation; Behavioral
Lead sponsor: William Brandenburg, MD; Industry
Eligibility: 18 Years and older
Enrollment: 1,000,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2099
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Relapsing Multiple Sclerosis
Interventions: CYB704, Ocrevus-EU, Ocrevus-US; Biological
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Maitland, Florida • Ormond Beach, Florida

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Menopausal Women, Insomnia
Interventions: Cognitive behavioral therapy for insomnia (CBT-i), Trazodone, Daridorexant; Behavioral · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years to 62 Years · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 5
States / cities: Boston, Massachusetts • Novi, Michigan • Winston-Salem, North Carolina + 2 more

Conditions: Child Anxiety, Anxiety Disorders, Anxiety, Anxiety Symptoms, Anxiety, Mild to Moderate, Pediatric Anxiety Disorders
Interventions: Therapist-Led CBT (telehealth, office-based, or hybrid), Guided Online CBT; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 7 Years to 18 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Miami, Florida • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Neoplastic Syndromes, Hereditary, Comparative Effectiveness Research
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,847 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Brain Injuries, Traumatic
Interventions: ICP + PbtO2 guided management strategy, ICP guided management strategy; Other
Lead sponsor: University of Michigan; Other
Eligibility: 14 Years and older
Enrollment: 1,094 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 48
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 38 more

Conditions: Breast Neoplasm, Colorectal Neoplasm, Female Reproductive System Neoplasm, Health Care Provider, Lymphoma, Plasma Cell Myeloma
Interventions: Best Practice, Educational Intervention, Internet-Based Intervention, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Pain, Physical Activity, Older Adults, Mild Cognitive Impairment
Interventions: MBCT+w, ALED; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Adavosertib, Olaparib, Ceralasertib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BGF, MITT; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 22,369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Complicated Intra-abdominal Infections
Interventions: ceftazidime/NXL104 + metronidazole, meropenem; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 9
States / cities: Los Angeles, California • Palm Springs, California • Detroit, Michigan + 5 more

Conditions: Influenza
Interventions: Fluzone, Flumist, Physiologic saline; Biological · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 49 Years
Enrollment: 1,952 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Kalamazoo, Michigan • Mount Pleasant, Michigan + 1 more

Conditions: Hematologic Neoplasms
Interventions: Piperacillin/Tazobactam (Tazocin); Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 31
States / cities: Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 25 more

Conditions: Obesity
Interventions: STAR - Study of Technology to Accelerate Research; Behavioral
Lead sponsor: Harvard Pilgrim Health Care; Other
Eligibility: 6 Years to 12 Years
Enrollment: 549 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Occipital Neuralgia
Interventions: Pulsed radiofrequency, Corticosteroid injection, Local anethestic injection; Procedure · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Baltimore, Maryland • Bethesda, Maryland

Conditions: Urea Cycle Disorders
Interventions: No Intervention Given; Other
Lead sponsor: Children's National Research Institute; Other
Eligibility: Up to 18 Years
Enrollment: 187 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Neurological Disorder, Autoimmune Diseases
Interventions: Mycophenolate Mofetil, Azathioprine; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 17
States / cities: Palo Alto, California • Miami, Florida • Chicago, Illinois + 12 more

Conditions: Macular Telangiectasia Type 2
Interventions: M-CHFM, CHFM; Combination Product
Lead sponsor: Neurotech Pharmaceuticals; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Walnut Creek, California • Grand Rapids, Michigan • Bellaire, Texas

Conditions: HIV Infections
Interventions: Saquinavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 20
States / cities: Hobson City, Alabama • Phoenix, Arizona • Paramount, California + 14 more

Conditions: Staphylococcal Skin Infections
Interventions: Daptomycin, Vancomycin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 25
States / cities: Mobile, Alabama • Chula Vista, California • Escondido, California + 22 more

Conditions: Keloid, Hypertrophic Scar, Cicatrix, Hypertrophic
Interventions: 0.5% hydrocortisone, silicone, vitamin E lotion, Onion extract gel, Cetearyl alcohol lotion; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Peripheral Arterial Disease, Claudication
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 21 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 12
States / cities: Bellevue, Washington • Bellingham, Washington • Everett, Washington + 6 more

Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions: Guanfacine (GUA), Methylphenidate (MPH); Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 3 Years to 5 Years
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Palo Alto, California • Boston, Massachusetts • Kansas City, Missouri + 2 more

Search by objective public record fields.

Health Ahead Comparative Effectiveness Study

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients

Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms

Kids FACE FEARS Comparative Effectiveness Research

Family History and Cancer Risk Study

Brain Oxygen Optimization in Severe TBI, Phase 3

Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer

Healthy Aging as Black Adults, In It Together: a Comparative Effectiveness Study of Chronic Pain and Cognitive Decline

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)

Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections

Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4

Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma

Study of Technology to Accelerate Research

Pulsed Radiofrequency vs. Steroid Injections for Occipital Neuralgia

PCORI Urea Cycle Disorder Study

Disease-Modifying Treatments for Myasthenia Gravis

A Study to Determine the Safety and Efficacy of NT-501 With M-CHFM

Safety and Effectiveness of Adding Saquinavir (FORTOVASE) in Soft Gel Capsule Form to an Anti-HIV Drug Combination in HIV-Infected Patients

Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA

A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars

Comparative Effectiveness Research Study of Peripheral Arterial Disease (PAD)

Treating Young Children With Attention Deficit Hyperactivity Disorder